# Synthekine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synthekine

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.synthekine.com
- Total disclosed funding: $340M
- Latest round: Series C (Dec 16, 2022)
- Investors on record: 11

## About

Synthekine Inc. is a biotechnology company focused on developing engineered cytokine therapeutics designed to enhance immune responses while minimizing toxicities, primarily for oncology and autoimmune diseases.Founded in 2018 and headquartered in Menlo Park, US, Synthekine Inc. specializes in engineered cytokine therapeutics. The company has secured a total of USD 150.00 mn through three funding rounds, with the latest being a Series C round in December 2022 led by The Column Group. CEO Debanjan Ray oversees the firm as it advances its innovative therapeutic offerings.Synthekine develops engineered cytokine therapeutics, including cytokine partial agonists and surrogate cytokine agonists. These products aim to target significant medical needs in oncology and autoimmune diseases, focusing on enhancing efficacy and safety. Their clinical pipeline features programs like SYNCAR-001 and STK-009, with targeted markets across North America, Europe, and Asia.Synthekine's revenue model relies on strategic partnerships with pharmaceutical companies, generating income from joint research agreements, milestone payments, and royalties linked to successful therapeutic developments. Notably, their collaboration with Merck involves licensing their surrogate cytokine agonist platform, facilitating early-stage research and potential clinical development.Following the Series C funding round in December 2022, which raised USD 150.00 mn, Synthekine plans to advance its differentiated therapeutic pipeline and support new clinical studies, particularly for its IL-12 partial agonist program. The company is focused on launching new products and expanding into markets in North America, Europe, and Asia within the next few years.

## Funding rounds

- Series C, Dec 16, 2022, $150M — The Column Group
- Series B, Jun 3, 2021, $108M — Canaan Partners, The Column Group, Lilly Asia Ventures, Omega Funds, Deerfield Management, RA Capital Management, Rock Springs Capital, Emerson Collective, Janus Henderson Investors, Samsara BioCapital, TCG Crossover Management
- Series A, Sep 17, 2020, $82M — Canaan Partners, The Column Group, Samsara BioCapital

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Rock Springs Capital — Series B
- Emerson Collective — Series B
- Janus Henderson Investors — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B